These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

349 related articles for article (PubMed ID: 31053413)

  • 1. Potentiating Oncolytic Virus-Induced Immune-Mediated Tumor Cell Killing Using Histone Deacetylase Inhibition.
    Jennings VA; Scott GB; Rose AMS; Scott KJ; Migneco G; Keller B; Reilly K; Donnelly O; Peach H; Dewar D; Harrington KJ; Pandha H; Samson A; Vile RG; Melcher AA; Errington-Mais F
    Mol Ther; 2019 Jun; 27(6):1139-1152. PubMed ID: 31053413
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of a new fusion-enhanced oncolytic immunotherapy platform based on herpes simplex virus type 1.
    Thomas S; Kuncheria L; Roulstone V; Kyula JN; Mansfield D; Bommareddy PK; Smith H; Kaufman HL; Harrington KJ; Coffin RS
    J Immunother Cancer; 2019 Aug; 7(1):214. PubMed ID: 31399043
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oncolytic virus immunotherapy for melanoma.
    Dharmadhikari N; Mehnert JM; Kaufman HL
    Curr Treat Options Oncol; 2015 Mar; 16(3):326. PubMed ID: 25777572
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The histone deacetylase inhibitor valproic acid lessens NK cell action against oncolytic virus-infected glioblastoma cells by inhibition of STAT5/T-BET signaling and generation of gamma interferon.
    Alvarez-Breckenridge CA; Yu J; Price R; Wei M; Wang Y; Nowicki MO; Ha YP; Bergin S; Hwang C; Fernandez SA; Kaur B; Caligiuri MA; Chiocca EA
    J Virol; 2012 Apr; 86(8):4566-77. PubMed ID: 22318143
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Talimogene laherparepvec (T-VEC) as cancer immunotherapy.
    Kohlhapp FJ; Zloza A; Kaufman HL
    Drugs Today (Barc); 2015 Sep; 51(9):549-58. PubMed ID: 26488034
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma.
    Kaufman HL; Kim DW; DeRaffele G; Mitcham J; Coffin RS; Kim-Schulze S
    Ann Surg Oncol; 2010 Mar; 17(3):718-30. PubMed ID: 19915919
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Talimogene Laherparepvec (T-VEC) and Other Oncolytic Viruses for the Treatment of Melanoma.
    Bommareddy PK; Patel A; Hossain S; Kaufman HL
    Am J Clin Dermatol; 2017 Feb; 18(1):1-15. PubMed ID: 27988837
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Concurrent delivery of GM-CSF and B7-1 using an oncolytic adenovirus elicits potent antitumor effect.
    Choi KJ; Kim JH; Lee YS; Kim J; Suh BS; Kim H; Cho S; Sohn JH; Kim GE; Yun CO
    Gene Ther; 2006 Jul; 13(13):1010-20. PubMed ID: 16525479
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical development of talimogene laherparepvec (T-VEC): a modified herpes simplex virus type-1-derived oncolytic immunotherapy.
    Harrington KJ; Puzanov I; Hecht JR; Hodi FS; Szabo Z; Murugappan S; Kaufman HL
    Expert Rev Anticancer Ther; 2015; 15(12):1389-403. PubMed ID: 26558498
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The safety of talimogene laherparepvec for the treatment of advanced melanoma.
    Gangi A; Zager JS
    Expert Opin Drug Saf; 2017 Feb; 16(2):265-269. PubMed ID: 27989216
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Herpes simplex virus oncolytic vaccine therapy in melanoma.
    Sivendran S; Pan M; Kaufman HL; Saenger Y
    Expert Opin Biol Ther; 2010 Jul; 10(7):1145-53. PubMed ID: 20515292
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular Pathways: Mechanism of Action for Talimogene Laherparepvec, a New Oncolytic Virus Immunotherapy.
    Kohlhapp FJ; Kaufman HL
    Clin Cancer Res; 2016 Mar; 22(5):1048-54. PubMed ID: 26719429
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cutaneous head and neck melanoma in OPTiM, a randomized phase 3 trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor for the treatment of unresected stage IIIB/IIIC/IV melanoma.
    Andtbacka RH; Agarwala SS; Ollila DW; Hallmeyer S; Milhem M; Amatruda T; Nemunaitis JJ; Harrington KJ; Chen L; Shilkrut M; Ross M; Kaufman HL
    Head Neck; 2016 Dec; 38(12):1752-1758. PubMed ID: 27407058
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Local Delivery of OncoVEX
    Moesta AK; Cooke K; Piasecki J; Mitchell P; Rottman JB; Fitzgerald K; Zhan J; Yang B; Le T; Belmontes B; Ikotun OF; Merriam K; Glaus C; Ganley K; Cordover DH; Boden AM; Ponce R; Beers C; Beltran PJ
    Clin Cancer Res; 2017 Oct; 23(20):6190-6202. PubMed ID: 28706012
    [No Abstract]   [Full Text] [Related]  

  • 15. A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor.
    Hu JC; Coffin RS; Davis CJ; Graham NJ; Groves N; Guest PJ; Harrington KJ; James ND; Love CA; McNeish I; Medley LC; Michael A; Nutting CM; Pandha HS; Shorrock CA; Simpson J; Steiner J; Steven NM; Wright D; Coombes RC
    Clin Cancer Res; 2006 Nov; 12(22):6737-47. PubMed ID: 17121894
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oncolytic viral therapy with a combination of HF10, a herpes simplex virus type 1 variant and granulocyte-macrophage colony-stimulating factor for murine ovarian cancer.
    Goshima F; Esaki S; Luo C; Kamakura M; Kimura H; Nishiyama Y
    Int J Cancer; 2014 Jun; 134(12):2865-77. PubMed ID: 24265099
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Talimogene laherparepvec: First in class oncolytic virotherapy.
    Conry RM; Westbrook B; McKee S; Norwood TG
    Hum Vaccin Immunother; 2018 Apr; 14(4):839-846. PubMed ID: 29420123
    [TBL] [Abstract][Full Text] [Related]  

  • 18. OncoVEX
    Estrada J; Zhan J; Mitchell P; Werner J; Beltran PJ; DeVoss J; Qing J; Cooke KS
    J Immunother Cancer; 2023 May; 11(5):. PubMed ID: 37164449
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytokine-armed oncolytic herpes simplex viruses: a game-changer in cancer immunotherapy?
    Wang H; Borlongan M; Kaufman HL; Le U; Nauwynck HJ; Rabkin SD; Saha D
    J Immunother Cancer; 2024 May; 12(5):. PubMed ID: 38821716
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metastatic melanoma in a 95 years old patient responding to treatment with talimogene laherparepvec followed by nivolumab.
    Naqash AR; Stroud G; Collichio FA; Muzaffar M; Sharma N; Walker P
    Acta Oncol; 2017 Oct; 56(10):1327-1330. PubMed ID: 28481677
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 18.